AGP Executive Report
Last update: 6 hours agoPublic Health & Outcomes: New Jersey saw the largest drop in death rate in the U.S. in recent federal data, with experts pointing to long-running state efforts to expand care for low-income residents. Health Policy & Access: Merck says it’s laying groundwork to expand access in low- and middle-income countries for alimatravir, an investigational once-monthly oral HIV PrEP pill, including early generic licensing and regional manufacturing. NJ Health & Safety Funding: New Jersey’s statewide EMS task force is facing shutdown risk after budget cuts left it with just 60 days of funding, threatening staffing and equipment upkeep. NJ Elections & Health-Adjacent Systems: NJ has hired an independent firm to investigate a software flaw that mistakenly added 6,000+ noncitizens to voter rolls in 2023-2024, with fewer than 400 reportedly voting. Biotech & Jobs: BeOne Medicines will invest an additional $300M to expand its Hopewell, NJ manufacturing and research campus, pushing total U.S. investment above $1B and aiming to create about 120 jobs. Medical Innovation: Johnson & Johnson’s FDA authorization clears its OTTAVA robotic surgical system for multiple soft-tissue general surgery procedures, with a limited rollout planned. Environment & Health: A new USDA equine study will launch in August to track horse health, welfare, and disease risks nationwide.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
